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Abstract Central to the pathogenesis of atypical hemolytic
uremic syndrome (aHUS) is over-activation of the alternative
pathway of complement. Following the initial discovery of
mutations in the complement regulatory protein, factor H,
mutations have been described in factor I, membrane cofactor
protein and thrombomodulin, which also result in decreased
complement regulation. Autoantibodies to factor H have also
been reported to impair complement regulation in aHUS.
More recently, gain of function mutations in the complement
components C3 and Factor B have been seen. This review
focuses on the genetic causes of aHUS, their functional
consequences, and clinical effect.
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HUS Hemolytic uremic syndrome
D+ve HUS Diarrhoeal-associated hemolytic uremic
syndrome
aHUS Atypical hemolytic uremic syndrome
AP Alternative pathway
CP Classical pathway
CCPs Complement control protein modules
RCA Regulators of complement activation
ESRF End-stage renal failure
SNPs Single nucleotide polymorphisms
Introduction
Hemolytic uremic syndrome (HUS) is characterized by the
triad of microangiopathic hemolytic anemia, thrombocyto-
penia, and acute renal failure. It has been classified as either
diarrhoeal-associated (D+ve) or non-diarrhoeal/atypical
(aHUS) [1].
Pathologically, glomerular capillary wall thickening is
seen due to endothelial cell swelling and accumulation of
material between the endothelial cell and the basement
membrane. This narrowing of the vessel lumen, in addition
to the platelet and fibrin thrombi, results in occlusion of the
glomerular capillaries. Fibrinoid necrosis of the afferent
arteriole associated with thrombosis may also be seen.
Mesangiolysis occurs early in the disease process and is
subsequently replaced by sclerotic changes. Early arterial
changes are variable, ranging from only mild endothelial
swelling to fibrinoid necrosis with occlusive thrombus
formation. Later in the disease process there is mucoid
intimal hyperplasia with narrowing of the vessel lumen.
Immunofluorescence demonstrates deposition of fibrin or
fibrinogen in the glomeruli and in the mesangium as well as
within the vessel walls. Granular deposits of complement
and immunoglobulins along the capillary loops of glomeruli
are occasionally seen [2].
D+ve HUS accounts for the majority of cases and is
usually caused by a preceding illness with vero cytotoxin-
producing bacteria, most commonly E. coli O157:H7 [3].
aHUS is rare, accounting for ∼10% of HUS and has a poor
prognosis with up to 50% of patients requiring ongoing
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or familial. Guidelines on the diagnosis of aHUS have
recently been published [5].
The past decade has revealed aHUS to be a disease
characterized by over-activation of the alternative complement
pathway (AP) (Fig. 1). Since the initial description of
mutations in the gene (CFH) encoding the complement
regulator factor H in aHUS, mutations in other complement
proteins and the presence of autoantibodies against comple-
ment regulators have been demonstrated in many cohorts of
aHUS patients. In this review, we will discuss the genetic and
autoimmune factors which predispose to aHUS and their
functional consequences.
Role of complement factor H
Factor H is an abundant serum glycoprotein (∼500 µg/ml)
whichiscomposed of 20 complementcontrolprotein modules
(CCPs) [6]. It is the most important fluid-phase regulator of
the AP. It acts as a cofactor for factor I-mediated proteolytic
inactivation of C3b, competes with factor B for C3b binding,
and accelerates the decay of the C3 convertase into its
components [7]. These functions are mediated through the
N-terminal four CCPs (CCP 1–4) [8]. Factor H also regulates
complement on host surfaces by binding to the glycosami-
noglycans of endothelial cells and exposed basement mem-
branes via its carboxyl-terminal domain (CCPs 19–20) [9].
Mutations in CFH associated with aHUS were first
demonstrated by Warwicker et al. [10] and have been
demonstrated to be the commonest genetic abnormality
found in many cohorts of aHUS patients [11–16]. The
majority of mutations are heterozygous and are located in
the exons encoding the C-terminal domain of the protein
which is responsible for mediating complement protection
on the cell surface (Fig. 2). These mutations do not usually
result in a quantitative deficiency of factor H.
CFH liesintheRCAgeneclusteratchromosome1q32and
is in close proximity to the genes (CFHR1–5)e n c o d i n gt h e
five factor H-related proteins. The CFHRs show a very high
degree of sequence identity to CFH (Fig. 2)a n da r et h o u g h t
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Fig. 1 Complement regulation. The alternative complement pathway
(AP) is a positive-feedback amplification loop. The AP constantly
undergoes tick over but can also be primed by the classical (CP) and
lectin (LP) pathways. The C3b that is formed interacts with factor B
(B), which is then cleaved by factor D (D) to form the AP C3
convertase (C3bBb). This enzyme complex is attached to the target
covalently via C3b while Bb is the catalytic serine protease subunit. It
is stabilized by binding properdin (P). Because C3 is the substrate for
this convertase, a powerful feedback loop is created. Unchecked, this
will lead to activation of the terminal complement pathway with
generation of the effector molecules; the anaphylatoxin C5a and the
membrane attack complex (MAC). To limit damage to host cells, the
AP is down-regulated by cofactor activity (CA) and decay accelerating
activity (DAA). CA results in the permanent inactivation of C3b to iC3b,
suchthatitisnolonger capableofbindingBandthuscannotformtheAP
convertase. CA requires both a cofactor protein (factor H [fH] or
membrane cofactor protein [MCP]) and a protease, factor I (fI). DAA is
the dissociation of the C3/C5 convertases. The decay accelerator protein,
in this example decay accelerating factor (DAF), displaces the catalytic
Bb from target-bound C3b. However, this C3b can bind another B and
then reform the convertase
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rearrangementsthroughnon-allelichomologousrecombination
(NAHR). Heinen et al. [17] showed that the aHUS-associated
factor H mutations S1191L, V1197A, and combined S1191L/
V1197A had arisen through gene conversion between CFHR1
and CFH. Venables et al. showed that a hybrid (fusion) gene
comprising the 21 N-terminal exons of CFH and the 2 C
terminal exons of CFHR1 has arisen through NAHR and is
associated with aHUS [18].
The functional consequences of aHUS-associated factor
H mutations have been studied, particularly those which
cluster in the C-terminal domain of the protein. Structural
analysis has shown that all such mutants are folded and
have only very localized structural perturbations [19].
Functional analysis has shown varied consequences on the
binding to heparin, C3b, and endothelial cells (Table 1).
However, all aHUS-associated factor H mutants show
impaired complement regulation at the cell surface using
erythrocyte lysis assays [19–21]. Thus it is hypothesized
that these C-terminal mutants fail to control complement
activation at the glomerular endothelium particularly where
basement membrane is exposed by the fenestrated endo-
thelium. Renal biopsy data from an aHUS patient with a
C-terminal mutant showed reduced factor H binding to
renal endothelium compared to wild-type, in keeping with
this hypothesis [22]. Additionally, it has been demonstrated
that aHUS-associated C-terminal factor H mutants have
reduced ability to bind to platelets, resulting in complement
activation on the surface of platelets. This in turn causes
platelet activation with aggregation and release of tissue-
factor-expressing micro-particles [23]. Thus complement
activation on the glomerular vasculature and on platelets is
thought to result in the pro-coagulant phenotype which
leads to aHUS.
As most CFH mutations associated with aHUS are
heterozygous, it has been postulated that these mutations
may exert a dominant negative effect [24]. Recent studies
have suggested that factor H may exist in monomer-dimer
Fig. 2 Complement factor H and complement factor H-related 1. The
figure demonstrates the 20 CCP modules of factor H (bottom) and the
five CCP modules of factor H-related protein 1 (top). The homology
of each factor H-related protein 1 CCP to the corresponding factor H
CCP is given as a percentage in the factor H-related protein 1 figure.
Note the homology between CCP18 of factor H and CCP 3 of factor
H-related protein 1 is given for the basic isoform. An acidic isoform
differs by three amino acids [62]. The glycosaminoglycan and C3b
binding sites of factor H are indicated on the diagram. Mutations in
CFH reported in aHUS are listed below the figure
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isolation in serum [25]. However, oligomerization of factor
H via glycosaminoglycans [26] or C3d [27] on cell surfaces
has been described. The extent to which oligomerization of
mutant factor H with wild-type may interfere with the
complement regulatory function has yet to be established.
TheCFH knockout mouse (Cfh
-/-) and a transgenic mouse
lacking the C-terminal region of factor H (Cfh
-/-Δ16–20)
have proved illuminating [28]. The Cfh
-/- mouse has very
low C3 levels due to uncontrolled turnover of the alternative
pathway and has a renal phenotype similar to membrano-
proliferative glomerulonephritis (MPGN) [29]. This is similar
to the phenotype of the factor H-deficient Norwegian–
Yorkshire pig [30]. In contrast, the Cfh
-/-Δ16–20 mouse has
higher plasma C3 levels than the Cfh
-/- mouse, and
spontaneously develops aHUS, not MPGN [31]. Thus, this
mouse model provides the first in vivo evidence that the CFH
mutations seen in aHUS impair endothelial cell surface
recognition, resulting in local complement dysregulation, while
controllingthealternativepathway inplasma.Goicoecheaet al.
[32] have also crossed the Cfh
-/-Δ16–20 with a C5-deficient
mouse to investigate the role of C5 activation in the
pathogenesis of aHUS. These C5
-/- CFH
-/-Δ16–20 mice do
not develop aHUS, suggesting a critical role downstream of
C 3 bg e n e r a t i o ni na H U S .
Mutations in membrane cofactor protein (MCP: CD46)
Membrane cofactor protein (MCP: CD46) is a membrane
glycoprotein present on the surface of all cells with the
exception of erythrocytes [33]. It consists of an extracellu-
lar segment comprising 4 CCPs, an alternatively spliced
STP region and a group of 12 amino acids of unknown
function. This is followed by a transmembrane domain and
an alternatively spliced cytoplasmic tail [33] (Fig. 3). As
with CFH and the CFHRs, the gene (MCP, CD46)
encoding MCP is located in the RCA cluster. MCP acts
as a cofactor for factor I in the proteolytic inactivation of
C3b and C4b bound to host cells.
Mutations in MCP have been demonstrated in up to 15%
of cohorts of aHUS patients [13, 34–37]. The majority of
MCP mutations in aHUS are heterozygous (∼75%), although
homozygous or compound heterozygous mutations are
reported [33]. Most MCP mutations cluster in the four
extracellular complement control protein domains of MCP
(Fig. 3), the region critical of complement regulation [33].
Around 75% of MCP mutations result in decreased cell
surfaceexpression and a quantitative deficiencyincomplement
regulation [33]. Functional analysis of the remaining muta-
tions has demonstrated a qualitative defect in complement
regulation. Ligand binding and cofactor assays of two
Table 1 Structural and functional consequences of mutations in aHUS
Mutant CCP Structural
changes
C3b/d binding Heparin binding Endothelial
cell binding
Hemolysis assay Reference




Y1142C 19 ND ND ND ND ↓
d [21]
W1157R 19 ND ↓↓ ND ND [87]
E1172X 20 ND ↓↓ ND ND [88, 89]
R1182S 20 Local ↓↓ ND ↓
c,d [19, 20]
W1183R 20 Local ↑↑ ND ↓
c [19]
W1183L 20 Local ↓↓
e ↓
a,b,e ↓
c [19, 86, 87, 90]




L1189R 20 Local ↑↑ ↑
a ↓
c,d [19, 20, 86]
L1189F 20 Local ↑↑ ND ↓
c,d [19, 20]
S1191W 20 ND ND ND ND ↓
d [20]
S1191L 20 Local ↑
e ↔ ND ↓
c,d [17, 19]
S1191L/V1197A 20 Local ↑
e ↔ ND ↓
c,d [17, 19]
V1197A 20 ND ↓
e ↓
e ND ↓
d [17, 20, 87, 90]
E1198K 20 ND ND ND ↓
b ↓
d [22]
R1210C 20 Local ↓↓
e ↓
b ↓
c [19, 20, 87, 89, 90]
R1215G 20 Local ↓↓ ↓
b ↓
c [19, 87, 89]
R1215Q 20 ND ↔↓ ↔
a ND [86]
P1226S 20 ND ↓↓ ND ND [87]
ND not done; Endothelial cell binding relates to either
amGEnC-1 [86]o r
bHUVEC [22, 88, 89] binding. Hemolysis assay using
crecombinant proteins
to compete with full-length CFH on human erythrocytes [19]o r
dusing patient serum on sheep erythrocytes [20]. To amalgamate these different hemolysis
assays, the arrows indicate the effect on cell surface complement regulation produced by the mutation.
eIndicates contradictory results
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strated reduced C3b binding and cofactor activity [13, 33, 34].
These assays of complement regulatory activity failed to
reveal any defect in two further normally expressed variants
(R69W; A304V), however further analysis of function using
cell surface assays demonstrated deficient control of the
alternative pathway [38]. Only one mutation (E145Q) so far
described has affected only C4b cofactor activity and the
surface expression of this mutant was increased [33, 35].
Complement factor I
Factor I is a highly specific serine protease that acts through
its proteolytic activity to control complement activation. It
consists of a catalytic light-chain disulfide bonded to a
heavy chain of unknown function. Factor I cleaves the α
chains of C3b and C4b in the presence of its cofactor
proteins: factor H for C3b [39, 40]; C4-binding protein
(C4BP) for C4b [41, 42]; and MCP [43] and complement
receptor 1 (CR1; CD35) [44, 45] for both. By inactivating
C3b and C4b through limited proteolytic cleavage, factor I
prevents the formation of the C3 and C5 convertases and
thus down-regulates the AP and classical pathway (CP).
Factor I is a serum glycoprotein predominantly synthesized
by the liver. Unlike many other complement regulatory
genes CFI does not reside in the RCA cluster at 1q32 but is
located at chromosome 4q25.
CFI mutations have been reported in 2–12% of aHUS
patients [13, 46–50]. The mutations are seen throughout the
molecule but are most commonly seen the serine protease
domain (Fig. 4).
In vitro analysis of aHUS-associated mutations has
demonstrated that the majority of mutations in CFI result
in a quantitative defect. Analysis has shown that even in
those mutations which have been shown to decrease
secretion, the serum factor I level can be within the normal
range [47]. Factor I is an acute-phase protein and this is
probably responsible for the large variation seen in factor I
levels in normal individuals (39–100 µg/ml) [51]. A
minority of mutations in CFI result in a qualitative defect
in complement regulation. Functional analysis of these
mutations demonstrated a loss of alternative and classical
cofactor activity, both in the fluid phase and on cell surfaces
[50, 52]. However, analysis of some CFI variants, using
recombinant proteins, has failed to demonstrate a functional
consequence (e.g. G243D [53]). It is possible that they are
not involved in the pathogenesis of disease or alternatively,
the defect may be too subtle to be detected by currently
available assays. This emphasizes the difficulty in attributing
disease causality to mis-sense mutations.
Thrombomodulin
Thrombomodulin (THBD) is a key component of the protein
C anticoagulation pathway and facilitates the activation of
protein C by thrombin [54]. Additionally, it enhances
thrombin-mediated activation of plasma procarboxypeptidase
B (TAFI) an inhibitor of fibrinolysis that also inactivates the
complement-derived anaphylatoxins C3a and C5a. THBD
has recently been shown to down-regulate the AP of
complement by accelerating factor I-mediated inactivation
of C3b in the presence of co-factors [55]. Mutations in the
gene (THBD) encoding thrombomodulin have recently been
shown to predispose to atypical HUS. These mutations
resulted in a loss of cofactor activity [55].
Factor B (CFB) mutations
Mutations have also recently been described in factor B
(CFB) although they are rare in the cohorts so far described
(0–3%) [56–58]. Factor B carries the catalytic site of the
complement AP convertase (C3bBb) and as such, unlike
previously described mutants associated with aHUS, acts as
Fig. 3 Membrane cofactor protein. The figure demonstrates clustering
of mutations in the four extracellular CCP domains of membrane
cofactor protein in aHUS. * denotes mutations resulting in decreased
cell surface expression of membrane cofactor protein
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associated with aHUS, are therefore activating mutations.
Goicoechea de Jorge et al. [56] elegantly described two
mechanisms through which these separate mutations led to
increased complement activation. One mutant (F286L)
showed enhanced formation of the C3bB proenzyme, which
will result in a more active enzyme in vivo. The other mutant
(K323E) formed a C3bBb enzyme more resistant to decay by
the complement regulators decay accelerating factor (DAF;
CD55) and factor H. This also caused increased enzyme
activity [56]. ThetwomutationsdescribedintheFrenchcohort
were also located in the von-Willebrand type A domain,
suggesting that this is a hotspot for mutations in aHUS. These
mutations were both demonstrated to be more active than the
wild-type protein, resulting in increased complement deposi-
tion on human glomerular endothelial cells [58].
C3 mutations
C3isthecentralcomponentofthecomplementcascade,critical
to activation by the classical, lectin, and alternative pathways.
C3 is cleaved to form the anaphylatoxin C3a and C3b, which is
highly reactive and can bind to cell surfaces via its reactive
thioester. C3b can then interact with factor B in the presence of
factor D to form the alternative pathway convertase, thus
introducing a positive-feedback amplification loop.
Recently mutations in C3 have been described in aHUS
patients [59, 60]. Functional analysis of five of the nine
mutations so far described has revealed decreased binding
to MCP with a consequent decrease in the ability of MCP
to act as a cofactor to inactivate C3b [60]. Thus, in vivo
these will act as gain of function mutations. In two of the
mutations, no functional impairment could be demonstrated
and in another two, the mutations resulted in a decreased
secretion of C3. How impaired secretion of C3 fits into the
current model of complement over-activation in aHUS is
yet to be resolved.
Autoantibodies to factor H/factor H-related 1
In addition to the genetic abnormalities described in aHUS,
autoantibodies to factor H have also been linked to disease
Fig. 4 Complement factor I.
The figure demonstrates the
modular structure of factor I
with aHUS-associated mutations
below.
$ denotes factor I mutants
that are secreted but have been
demonstrated to have decreased
activity. * denotes factor I
mutants that have impaired
secretion
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suggestthattheonset of diseaseor diseaserecurrencecorrelates
with the presence of factor H autoantibodies. The titre of these
antibodies may also spontaneously decline with time.
Jozsi et al. demonstrated using recombinant fragments of
factor H that the autoantibodies in five patients bound to the
C-terminus of the molecule [65]. This is an area of factor H
that is responsible for cell surface protection and is a
hotspot for mutations. Factor H autoantibodies have been
demonstrated to impair the binding of factor H to C3b and
are associated with increased hemolysis of sheep erythrocytes
in patient plasma [65]. In the Newcastle cohort, the majority
of the autoantibodies also bound to CCPs19–20 [61].
An 80-kb-long genomic deletion of CFHR1 and CFHR3
has been associated with an increased risk of aHUS [66]. It
was subsequently demonstrated that this complete deficiency
ofCFHR1a n dCFHR3 was strongly associated with factor H
autoantibodies [64]. More detailed analysis has subsequently
revealed aHUS patients with CFHR1d e f i c i e n c yr e s u l t i n g
from point mutations in CFHR1[ 62] or from a deletion
incorporating CFHR1 and CFHR4[ 61, 62]. Thus the
association between the CFHR1/CFHR3 deletion and the
presence of autoantibodies in aHUS is probably related to
the absence of CFHR1. It should be noted, however, that
deficiency of CFHR1 is not a prerequisite for formation of
autoantibodies as Moore et al. describe three patients with no
evidence of deficiency of CFHR1 or CFHR3 and high titres
of autoantibodies [61].
The two C-terminal CCPs (4 and 5) of CFHR1 are
almost identical to CCPs19–20 of factor H (Fig. 2) and it is
not surprising therefore that autoantibodies to CCPs19–20
of factor H also bind to CCPs 4–5o fCFHR1[ 61]. It has
been suggested that the antibodies generated in the absence
of CFHR1 are different to those in its presence [62] and it is
interesting that one of the patients with two copies of
CFHR1 had antibodies against factor H CCPs1–4[ 61], the
region of the molecule responsible for cofactor and decay
accelerating activity. Although most individuals with auto-
antibodies and CFHR1 deficiency do generate autoanti-
bodies to CCP19–20, antibodies to this epitope are seen in
the presence of CFHR1[ 61].
Other complement genes
A mutation (Q433P) in the gene (Clu) encoding clusterin
has been described in one family with aHUS [67]. Clusterin
isa serum regulator ofthe terminalpathwayofcomplement,it
is predominantly produced by the liver, but is also released by
activated platelets [68, 69]. In addition to the Clu mutation,
the patient also had a functionally significant MCP mutation.
This was of paternal origin while the Clu mutation came
through the maternal line. Functional analysis of the mutant
clusterin revealed decreased binding to C5b-7 and reduced
complement regulation in a hemolytic assay. Serum from this
patient also induced complement deposition on platelets and
their activation. Although this mutation has been demonstrated
to be functionally significant, aHUS only occurred in the
presence of an MCP mutation known to predispose to aHUS.
This is in keeping with the hypothesis that multiple concurrent
factors may be necessary in individual patients for disease
manifestation [70]. Mutation screening of other complement
genes has been undertaken in aHUS. DAF is another
complement regulatory gene located in the RCA cluster. It
encodes a widely expressed membrane bound regulatory
protein which accelerates the decay of either C4bC2a or
C3bBb and the corresponding C5 convertases. Mutation
screening of DAF in two cohorts has shown only one
mutation which did not impair regulatory activity [56, 71].
Complement receptor 1 (CR1) is a cell surface complement
regulator with cofactor and decay accelerating activity for
both the AP and CP. In the one reported cohort of patients, no
mutations were detected [36]. Screening of the genes
(CFHR1–5) encoding the factor H-related proteins in one
cohort of aHUS individuals failed to reveal mutations [37]
while no causative mutations in CFHR5 were demonstrated in
a separate cohort [72]. However, Abarrategui-Garrido have
shown that deficiency of factor H-related protein 1 is in some
aHUS patients secondary to point mutations in CFHR1.T h e y
also described a novel variant of CFHR1, which is probably a
result of gene conversion between CFH and CFHR1.T h i s
variant is strongly associated with aHUS [62].
Incomplete penetrance
Incomplete penetrance has been reported for all the genes
associatedwithaHUS.FormutationsinCFH, CFI, MCP,a n d
CFB penetrance is ∼50% while in the limited number of C3
mutations described to date, the penetrance is lower [59].
It has now been demonstrated that for disease to
manifest in an individual a combination of mutations, risk
haplotypes, and single nucleotide polymorphisms (SNPs)
must be present [13, 31, 64, 66, 73–77]. The CFH risk
haplotype for aHUS (CFH–H3) contains a SNP in the
region of CFH responsible for cofactor activity. Functional
analysis has demonstrated that the risk variant, CFH-Val62,
has a subtle decrease in cofactor activity compared to the
protective variant, in keeping with the minor structural
differences between these SNPs [8, 78].
Similar risk haplotypes have also been described in MCP
[73, 74] with a haplotype termed MCPggaac conferring a
two-fold increased risk of aHUS compared with controls
[74]. This contains two SNPs in the MCP promoter and
reporter gene assays suggests that these haplotype differences
may reduce transcriptional activity in the risk haplotypes by
Pediatr Nephrol (2010) 25:2431–2442 243725% [74, 75]. In vivo differences have not been demonstrat-
ed between the haplotypes, however, and it is possible that
this is only revealed at times of cellular activation [74, 75].
C4b binding protein is the predominant regulator of the
classical pathway of complement in the fluid phase [79,
80]. In addition to classical pathway activity, C4BP is also a
weak regulator of the alternative pathway, acting as a
cofactor for the factor I mediated cleavage of C3b. It is
comprised of 7 identical α chains and a single β chain.
C4BP is encoded by two genes, C4BPA and C4BPA in the
RCA cluster. A SNP in C4BP (R240H) was associated with
aHUS in cohorts from the UK and France [77]. Functional
analysis of the change demonstrated normal secretion of the
protein and normal ability to regulate classical and lectin
pathways. The R240H SNP was, however, unable to down
regulate the alternative pathway as efficiently as wild-type
[77]. Manyofthe aHUSpatientswiththispolymorphismalso
carried mutations in other complement genes associated with
aHUS, and it is possible that this change is an additive risk
factorfor aHUS. However, thisassociationwas not confirmed
in a separate Spanish cohort of patients [81].
The CFHR1/CFHR3 deletion is another risk factor for
the development of aHUS as described previously.
Thus, there are now described a number haplotypes and
SNPs which act in concert with mutations in complement
genes and inhibitory autoantibodies. Only when an unfa-
vorable group of risk factors co-segregate will aHUS
develop. Even then the disease may not manifest until
middle age, suggesting that a trigger is required to reveal
the latent complement regulatory deficiency. These precip-
itating events are hypothesized to be the endothelial cell
insults which have historically been associated with aHUS
[82]. In an Italian cohort of patients with MCP mutations,
infection precipitated the onset of disease in all individuals.
In those with factor H mutations, 70% of cases were
preceded by infection, and pregnancy and drugs each
accounted for 4%. For CFI mutations 40% were preceded
by pregnancy and 60% were precipitated by infection [13].
Thus, the environmental trigger initiates the positive
feedback loop of complement and in susceptible individuals
unable to control complement turnover, disease will manifest.
Genotype: phenotype effects
The prognosis of patients correlates to a certain extent with
the genetic defect. Those with CFH mutations carry the
worst outcome. Within a year after disease onset, 60–70%
[13, 49] of patients with CFH mutations die or reach ESRF.
This genotype: phenotype is not absolute, however. This
was best illustrated by analysis of 13 individuals carrying
the same mutation (R1210C) [76]. As a whole the group
did poorly, eight patients developed end-stage renal failure
and one patient had chronic kidney disease, but there was
one individual with this mutation who had a single episode
of aHUS with no long-term sequelae. It is noteworthy that
of this group only this individual did not have additional
genetic risk factors for aHUS. Thus, although mutations in
CFH are a poor prognostic indicator, it appears that other
genetic risk factors do modify disease outcome.
In comparison to those with CFH mutations, the outcome
of patients with MCP mutations is good, with ∼80%
remaining dialysis-independent [13, 49]. Recurrence of
disease in MCP-associated aHUS is frequent however. In
the minority of cases with MCP mutations that do go onto
develop ESRF, it is likely that additional genetic modifiers
are present.
In those with CFI-associated aHUS, the prognosis is
intermediate between CFH and MCP-associated aHUS. A
report from an Italian cohort of patients suggested that in
those with CFI-associated aHUS, >60% of patients devel-
oped ESRF [13]. In the French cohort, in those with
mutations in CFI, around 50% of patients died or
progressed to ESRF within 2 years of the initial episode
of aHUS, while ∼30% of individuals recovered with no
disease recurrences [49]. Bienaime et al. demonstrated that
the severity of disease was influenced by additional genetic
factors. In particular, those with an associated deletion of
CFHR1 had a significantly worse outcome [50].
To date, all those individuals with factor H autoanti-
bodies are children [61, 63] and less than 50% have gone
on to develop ESRF [61, 63].
Definite clinical correlations have yet to emerge in those
with CFB and C3 mutations due to the limited number of
cases so far reported. The outcome of patients with CFB
mutations would appear poor, however, with the majority of
patients developing ESRF. Of the 14 individuals reported
with C3-associated aHUS, eight developed ESRF and one
developed chronic renal impairment.
In addition to pre-determining the outcome of aHUS in
the native kidneys, the genetic predisposition also affects
the aHUS recurrence rate after renal transplantation. The
complement regulatory defect in those with mutations in
the membrane bound, MCP, is corrected by an allograft
bearing wild-type MCP and so the recurrence rate is low. In
those with mutations in CFH and CFI, which are produced
in the liver, a renal transplant does not correct the defect so
the recurrence rate is high [83–85].
Summary
Although many different alterations in complement genes
have been reported to predispose to aHUS, the downstream
consequence of all is over-activation of the alternative
pathway of complement on the glomerular vasculature. It is
2438 Pediatr Nephrol (2010) 25:2431–2442increasingly becoming clear that a combination of mutations,
SNPs, and haplotypes are required for disease to manifest
upon exposure to an environmental trigger. The genetic
predisposition also determines the prognosis after the initial
episode and following renal transplantation.
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Questions
(Answers appear following the reference list)
1. Familial atypical HUS
a) Is completely penetrant.
b) Has been causally associated with Eculizumab
treatment.
c) Is predisposed to by mutations in complement
factor H.
d) Always presents in childhood.
e) Never recurs following renal transplantation.
2. In atypical HUS
a) Complement factor B mutations are the commonest
genetic cause.
b) Individuals with membrane cofactor mutations
never have disease recurrence.
c) Individuals who present during pregnancy never
have complement mutations.
d) Complement factor H mutations are the rarest
genetic cause.
e) Autoantibodies to factor H have been associated
with disease.
3. Atypical hemolytic uremic syndrome is associated with
mutations in complement regulatory genes. A low recur-
rence rate of aHUS post renal transplantation is associated
with mutations in which of the following genes?
a) Complement factor I
b) Complement factor H
c) Membrane cofactor protein
d) Complement factor B
e) C3
4. In aHUS, autoantibodies to complement factor H
a) Do not result in impaired complement regulation at
host cell surfaces.
b) Are associated with a deletion of the CFHR1 and
CFHR3 genes.
c) Always bind to the C-terminal region of comple-
ment factor H.
d) Never cross react with the complement factor H-
related 1 protein.
e) Cannot be removed by plasma exchange.
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